Zepbound (tirzepatide) produces greater average weight loss than Wegovy (semaglutide) — 20.2% versus 14.9% of body weight in the SURMOUNT-5 head-to-head trial. Wegovy has a proven cardiovascular outcomes label (SELECT trial) and a daily oral option for needle-averse patients launched in January 2026. Zepbound is the stronger choice on efficacy alone. Wegovy is the stronger choice if cardiovascular protection or needle avoidance is the priority.
This is the comparison that actually matters for most patients choosing a weight loss medication in 2026. Both Wegovy and Zepbound are FDA-approved specifically for chronic weight management, which makes the choice cleaner than the Ozempic vs Mounjaro comparison where one drug carries a diabetes label and the other is being used off-label for weight loss.
The same molecules, different brand names
Wegovy contains semaglutide at doses up to 2.4mg weekly (or up to 7.2mg in the Wegovy HD formulation approved March 2026). Zepbound contains tirzepatide at doses up to 15mg weekly. Wegovy is made by Novo Nordisk. Zepbound is made by Eli Lilly. The underlying molecules are the same ones in Ozempic and Mounjaro respectively.
The mechanism difference is what drives the efficacy gap. Wegovy activates one receptor (GLP-1). Zepbound activates two (GLP-1 and GIP). That dual activation produces synergistic effects on appetite suppression, insulin sensitivity, and fat metabolism that exceed what GLP-1 agonism alone achieves.
The head-to-head evidence — SURMOUNT-5
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, was the first direct randomised comparison of tirzepatide and semaglutide specifically for weight loss. It enrolled adults with obesity or overweight and at least one weight-related comorbidity, who did not have type 2 diabetes.
At 72 weeks, participants on Zepbound (tirzepatide 10mg or 15mg) lost an average of 20.2% of their body weight, equivalent to roughly 50 pounds. Participants on Wegovy (semaglutide 2.4mg) lost 14.9%. The difference was statistically significant and clinically meaningful. Fewer participants stopped Zepbound due to gastrointestinal side effects than Wegovy (2.7% versus 5.6%).
Zepbound 10/15mg: 20.2% average body weight reduction at 72 weeks (~50 lbs)
Wegovy 2.4mg: 14.9% average body weight reduction at 72 weeks (~38 lbs)
Discontinuation due to GI side effects: 2.7% (Zepbound) vs 5.6% (Wegovy)
Trial population: Adults with obesity, no type 2 diabetes, at least one comorbidity
Wegovy HD — the 2026 development that changes the calculation
In March 2026, the FDA approved Wegovy HD — a 7.2mg formulation of semaglutide, nearly triple the previous maximum dose of 2.4mg. The STEP UP trial showed 20.7% average weight loss at this dose, narrowing the efficacy gap with Zepbound meaningfully. For patients who tolerate and respond to semaglutide but have plateaued at 2.4mg, Wegovy HD represents a significant step up without switching mechanisms.
Wegovy HD is not yet widely available and its long-term safety at the higher dose is less established than the 2.4mg formulation. But it complicates the simple "Zepbound wins on efficacy" narrative that SURMOUNT-5 established.
Wegovy's oral option — January 2026
Oral Wegovy (semaglutide tablet, up to 25mg daily) was FDA-approved in December 2025 and launched January 2026. The OASIS 4 trial showed 14.4% average weight loss at 64 weeks — comparable to the injectable formulation in terms of average outcomes, with 30% of participants achieving at least 20% weight loss. For patients who are strongly needle-averse, oral Wegovy is the only FDA-approved oral weight loss medication in the GLP-1 class. Zepbound has no oral formulation.
Where Wegovy has the clearer advantage
Wegovy's SELECT trial demonstrated a significant reduction in major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease, making it the only weight loss drug with a proven cardiovascular outcomes label. For patients where cardiovascular risk reduction is the primary treatment goal alongside weight management, this distinction matters considerably. Zepbound's cardiovascular data is expected from SURPASS-CVOT in 2027.
| Factor | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| Average weight loss | 14.9% (SURMOUNT-5) | 20.2% (SURMOUNT-5) |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Cardiovascular label | Yes — SELECT trial | Pending — 2027 |
| Oral option | Yes — launched Jan 2026 | No injectable only |
| High dose option | Wegovy HD 7.2mg (March 2026) | 15mg maximum |
| List price monthly | ~$1,349 (injectable) | ~$1,086 (injectable) |
| Self-pay programme | NovoCare: $199-349/mo injectable, $149-299/mo oral | LillyDirect: $299-449/mo vials |
| Medicare coverage (2026) | GLP-1 Bridge programme $50 copay | GLP-1 Bridge programme $50 copay |
| GI discontinuation rate | 5.6% (SURMOUNT-5) | 2.7% (SURMOUNT-5) |
| Long-term safety data | More established — approved 2021 | Approved 2023 |
Who should choose which
What both drugs share
Both require long-term use to maintain results. Weight typically returns after stopping either medication. Neither is a short course treatment. Both carry the same class warnings for thyroid C-cell tumours (rodent data, unconfirmed in humans at clinical doses), pancreatitis, and gallbladder disease. Both are contraindicated in pregnancy, with Novo Nordisk and Eli Lilly both recommending discontinuation at least two months before attempting conception. Both produce lean mass loss alongside fat loss, and resistance training with adequate protein intake is strongly recommended with either.